7:00 PM Dr Love
Introduction and meeting overview

Module I: Management of Advanced NSCLC

Agree, disagree or in between?
In the near future, lung cancer tumor specimens will be routinely assayed for expression of EGFR by FISH, the presence of EGFR mutations and K-ras status just as estrogen receptor and HER2 are now routinely assayed in breast cancer.

7:15 PM Group discussion

Agree, disagree or in between?
Cost, reimbursement and regulatory issues aside, the optimal first-line therapy for patients with tumors that do not have EGFR mutations and are not eligible for E4599 is chemotherapy with cetuximab.

7:40 PM Group discussion

Agree, disagree or in between?
Patients with EGFR TK domain mutations or clinical features predictive of sensitivity to erlotinib should be offered erlotinib or an erlotinib-based regimen as initial therapy for metastatic or recurrent disease.

8:15 PM Group discussion

Module II: Management of Stage III Disease

Agree, disagree or in between?
Biologic agents do not have a current routine role in the management of Stage IIIB NSCLC, but there is an urgent need to evaluate in clinical trials both bevacizumab and cetuximab administered concurrently with chemoradiation therapy.

8:40 PM Group discussion

Module III: Adjuvant Therapy of NSCLC

Agree, disagree or in between?
If biologic therapy is found to be effective in adjuvant therapy of NSCLC, it will likely be proven more effective if administered for a prolonged or indefinite period, as is the case with imatinib in GIST.

9:05 PM Group discussion